Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical companies are creating new obesity drugs that will soon hit the market—with 16 new drugs potentially launching in the next five years. These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031.

Our report on the obesity drug market landscape analyzes obesity treatments, market concentration, obesity drug candidates, public and private market considerations, and more.

Download the report now to find out how this growing industry can set your clients up for long-term success.